BioRad Laboratories stockholders have re-elected Louis Drapeau and Albert Hillman as class A directors, and Deborah Neff, Alice Schwartz, and Norman Schwartz as class B directors.
Nanosphere announced the appointment of Ken Bahk as its chief strategy officer, a new position, and that CTO Tim Patno and board member Chad Mirkin will be leaving the company.
Bahk was part of Nanosphere's initial team, and served with the company until 2008. In his new role at Nanosphere, he will be responsible for driving strategic plans and revenues in molecular diagnostics.
He is currently a director of investments at Lurie Investments and previously served as the chair of strategic opportunities for the Association for Molecular Pathology.